Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Hui-wen Lue"'
Autor:
Hui-wen Lue, Daniel S. Derrick, Soumya Rao, Ahna Van Gaest, Larry Cheng, Jennifer Podolak, Samantha Lawson, Changhui Xue, Devin Garg, Ralph White, III, Christopher W. Ryan, Justin M. Drake, Anna Ritz, Laura M. Heiser, George V. Thomas
Publikováno v:
Cell Reports Medicine, Vol 2, Iss 5, Pp 100267- (2021)
Summary: The lack of effective treatment options for advanced non-clear cell renal cell carcinoma (NCCRCC) is a critical unmet clinical need. Applying a high-throughput drug screen to multiple human kidney cancer cells, we identify the combination of
Externí odkaz:
https://doaj.org/article/81d895defe654fc78a2802b6f737cb09
Autor:
Bei Gao, Hui-Wen Lue, Jennifer Podolak, Sili Fan, Ying Zhang, Archana Serawat, Joshi J. Alumkal, Oliver Fiehn, George V. Thomas
Publikováno v:
Metabolites, Vol 9, Iss 5, p 82 (2019)
As the most common cancer in men, prostate cancer is molecularly heterogeneous. Contributing to this heterogeneity are the poorly understood metabolic adaptations of the two main types of prostate cancer, i.e., adenocarcinoma and small cell neuroendo
Externí odkaz:
https://doaj.org/article/b85f2a7bfa8a492da05c087ba3458051
Autor:
Hui-Wen Lue, Xiaojian Yang, Ruoxiang Wang, Weiping Qian, Roy Z H Xu, Robert Lyles, Adeboye O Osunkoya, Binhua P Zhou, Robert L Vessella, Majd Zayzafoon, Zhi-Ren Liu, Haiyen E Zhau, Leland W K Chung
Publikováno v:
PLoS ONE, Vol 6, Iss 11, p e27720 (2011)
LIV-1, a zinc transporter, is an effector molecule downstream from soluble growth factors. This protein has been shown to promote epithelial-to-mesenchymal transition (EMT) in human pancreatic, breast, and prostate cancer cells. Despite the implicati
Externí odkaz:
https://doaj.org/article/adc77c83e6674391a2395e669c136a33
Autor:
Leland W.K. Chung, Takeo Nomura, Chia-Yi Chu, Hui-Wen Lue, Wei Ping Qian, Haiyen E. Zhau, Jonathan J. Havel, Wen-Chin Huang
Supplementary Data from β2-Microglobulin Signaling Blockade Inhibited Androgen Receptor Axis and Caused Apoptosis in Human Prostate Cancer Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3071ee2da0d5576c820718c912751464
https://doi.org/10.1158/1078-0432.22439868
https://doi.org/10.1158/1078-0432.22439868
Autor:
Leland W.K. Chung, Takeo Nomura, Chia-Yi Chu, Hui-Wen Lue, Wei Ping Qian, Haiyen E. Zhau, Jonathan J. Havel, Wen-Chin Huang
Purpose: β2-Microglobulin (β2M) has been shown to promote osteomimicry and the proliferation of human prostate cancer cells. The objective of this study is to determine the mechanism by which targeting β2M using anti-β2M antibody inhibited growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::293f367686014d4ddef01cd889661ded
https://doi.org/10.1158/1078-0432.c.6517272.v1
https://doi.org/10.1158/1078-0432.c.6517272.v1
Autor:
Ralph White, Soumya Rao, Laura M. Heiser, Hui-wen Lue, Anna Van Gaest, Larry C. Cheng, Daniel S. Derrick, George Thomas, Christopher W. Ryan, Devin Garg, Changhui Xue, Jennifer Podolak, Samantha Lawson, Anna Ritz, Justin M. Drake
The lack of effective treatment options for advanced non-clear cell renal cell carcinoma (NCCRCC) is a critical unmet clinical need. Applying a high throughput drug screen to multiple human kidney cancer cells, we identified the combination of the VE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ad2fb929c1d762e7dc9df75e54bd085
https://doi.org/10.1101/2020.07.25.221507
https://doi.org/10.1101/2020.07.25.221507
Autor:
Jennifer Podolak, Bei Gao, Oliver Fiehn, George Thomas, Sili Fan, Joshi J. Alumkal, Hui Wen Lue, Ying Zhang, Archana Serawat
Publikováno v:
Metabolites, vol 9, iss 5
Metabolites, Vol 9, Iss 5, p 82 (2019)
Metabolites
Metabolites, Vol 9, Iss 5, p 82 (2019)
Metabolites
As the most common cancer in men, prostate cancer is molecularly heterogeneous. Contributing to this heterogeneity are the poorly understood metabolic adaptations of the two main types of prostate cancer, i.e., adenocarcinoma and small cell neuroendo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f34194a89a2904723dc8149b4b30deb
https://escholarship.org/uc/item/58j376pr
https://escholarship.org/uc/item/58j376pr
Autor:
Kevin S. Kolahi, Kent L. Thornburg, Soumya Rao, Christopher L. Amling, Daniel K. Nomura, Charles Truillet, Larry C. Cheng, Jen-Jane Liu, Sharon M. Louie, Chang Hui Xue, Jennifer Podolak, Michael J. Evans, George Thomas, Valerie B. O'Donnell, Justin M. Drake, Juha Rantala, Jeffrey W. Tyner, Devin Garg, Anna Ritz, Hui Wen Lue, Ann Martinez-Acevedo, Kimberly E. Anderson
Publikováno v:
Genes & development, vol 31, iss 20
There is limited knowledge about the metabolic reprogramming induced by cancer therapies and how this contributes to therapeutic resistance. Here we show that although inhibition of PI3K–AKT–mTOR signaling markedly decreased glycolysis and restra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8d52a488abc0b052b591e447208c54b
https://europepmc.org/articles/PMC5733498/
https://europepmc.org/articles/PMC5733498/
Autor:
Timothy A. Newby, Jennifer Podolak, Joshi J. Alumkal, Eric J. Small, Kristi M. Eilers, Rahul Aggarwal, Hui-wen Lue, Julie N. Graff, Susan B. Olson, Tomasz M. Beer, George Thomas, Erin Tucker, Rachel Slottke, Jack F. Youngren
Publikováno v:
Oncotarget
// Jennifer Podolak 1 , Kristi Eilers 1 , Timothy Newby 1 , Rachel Slottke 1 , Erin Tucker 1 , Susan B. Olson 2 , Hui-Wen Lue 1 , Jack Youngren 3 , Rahul Aggarwal 3 , Eric J. Small 3 , Julie N. Graff 1 , Joshi J. Alumkal 1 , Tomasz M. Beer 1 and Geor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd4256d3e886924c0a6e6b788c35d30f
https://pubmed.ncbi.nlm.nih.gov/29069718
https://pubmed.ncbi.nlm.nih.gov/29069718
Autor:
Chia-Yi Chu, Leland W.K. Chung, Wen-Chin Huang, Jonathan J. Havel, Haiyen E. Zhau, Hui-Wen Lue, Takeo Nomura, Weiping Qian
Publikováno v:
Clinical Cancer Research. 14:5341-5347
Purpose: β2-Microglobulin (β2M) has been shown to promote osteomimicry and the proliferation of human prostate cancer cells. The objective of this study is to determine the mechanism by which targeting β2M using anti-β2M antibody inhibited growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e32619ec01c356df15cf9e01d7f7b801
https://doi.org/10.1158/1078-0432.ccr-08-0793
https://doi.org/10.1158/1078-0432.ccr-08-0793